Ionis Pharmaceuticals logged a 2.4% change during today's evening session, and is now trading at a price of $75.89 per share.
Ionis Pharmaceuticals returned gains of 96.8% last year, with its stock price reaching a high of $86.74 and a low of $36.93. Over the same period, the stock outperformed the S&P 500 index by 72.3%. More recently, the company's 50-day average price was $74.9. Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. Based in Carlsbad, CA, the Large-Cap Health Care company has 1,402 full time employees. Ionis Pharmaceuticals has not offered a dividend during the last year.
The Business Is Unprofitable and Its Balance Sheet Is Highly Leveraged:
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue (k) | $729,264 | $810,456 | $587,367 | $787,647 | $705,138 | $943,711 |
| Operating Margins | -24% | -4% | -70% | -45% | -67% | -40% |
| Net Margins | -61% | -4% | -46% | -47% | -64% | -40% |
| Net Income (k) | -$444,263 | -$28,597 | -$269,722 | -$366,286 | -$453,897 | -$381,387 |
| Net Interest Expense (k) | $9,510 | $9,349 | $8,122 | $12,660 | $16,994 | $17,262 |
| Depreciation & Amort. (k) | $13,365 | $15,487 | $14,328 | $10,292 | $9,614 | $10,008 |
| Diluted Shares (k) | 139,612 | 160,340 | 141,848 | 143,190 | 149,514 | 182,331 |
| Earnings Per Share | -$3.18 | -$0.2 | -$1.9 | -$2.56 | -$3.04 | -$2.38 |
| EPS Growth | n/a | 93.71% | -850.0% | -34.74% | -18.75% | 21.71% |
| Avg. Price | $54.17 | $40.86 | $35.3 | $50.59 | $35.05 | $74.48 |
| P/E Ratio | -17.03 | -204.3 | -18.58 | -19.76 | -11.53 | -31.29 |
| Free Cash Flow (k) | $772 | $18,844 | -$290,091 | -$331,318 | -$546,227 | -$320,027 |
| CAPEX (k) | $35,120 | $11,955 | $15,721 | $23,805 | $45,280 | $51,444 |
| EV / EBITDA | -48.41 | -336.5 | -14.95 | -23.7 | -13.15 | -35.73 |
| Total Debt (k) | $539,112 | $59,713 | $1,194,233 | $1,308,360 | $1,253,062 | $1,812,405 |
| Current Ratio | 3.56 | 9.75 | 7.07 | 5.9 | 8.47 | 3.83 |
Ionis Pharmaceuticals has growing revenues and increasing reinvestment in the business, an excellent current ratio of 3.83, and positive EPS growth. However, the firm suffers from negative cash flows and High Levels of Debt.
Ionis Pharmaceuticals does not have a meaningful trailing P/E ratio since its earnings per share are negative. Its forward EPS guidance is negative too, at $-0.74. The average P/E ratio for the Health Care sector is 22.94. Furthermore, Ionis Pharmaceuticals is likely overvalued compared to the book value of its equity, since its P/B ratio of 25.62 is higher than the sector average of 3.19.
Ionis Pharmaceuticals Has an Analyst Consensus of Strong Upside Potential:
The 23 analysts following Ionis Pharmaceuticals have set target prices ranging from $74.0 to $130.0 per share, for an average of $104.91 with a buy rating.
Ionis Pharmaceuticals has an above average percentage of its shares sold short because 13.6% of the company's shares are sold short. Institutions own 107.3% of the company's shares, and the insider ownership rate stands at 0.61%, suggesting a small amount of insider investors. The largest shareholder is FMR, LLC, whose 15% stake in the company is worth $1,863,603,166.
